Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Clinical approach to primary membranoproliferative glomerulonephritis].

Nephrologie & therapeutique - 1 Apr 2016

Fakhouri Fadi

Abstract excerpt

Membranoproliferative glomerulonephritis represent a heterogeneous group of nephropathies. During the last five years, our understanding of membranoproliferative glomerulonephritis has greatly improved. Animal models and the study of complement genetics led to the dissection of the physiopathology of membranoproliferative glomerulonephritis, to the individualization of a new entity, C3 glomerulopathy, and to a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Complement C3
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Genetic Predisposition to Disease

Share to Glomerulonephritis, Membranoproliferative

Share to Mycophenolic Acid

Share to Treatment Outcome

Source

Identifiers

PMID: 26972096
DOI: 10.1016/j.nephro.2016.01.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Clinical approach to primary membranoproliferative glomerulonephritis].PMID 26972096Read ↗

Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatmentSemantic proximity Read ↗

Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GNSemantic proximity Read ↗

C3 glomerulopathy: what's in a name?Semantic proximity Read ↗

C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.Semantic proximity Read ↗

Targeted Complement Treatments in Glomerulopathies: A Comprehensive ReviewSemantic proximity Read ↗

C3 Glomerulopathy: A Current Perspective in an Evolving LandscapeSemantic proximity Read ↗

Acquired and genetic determinants of disease phenotype and therapeutic strategies in C3 glomerulopathy and immunoglobulin-associated MPGNSemantic proximity Read ↗

Recent insights into C3 glomerulopathySemantic proximity Read ↗

Evolving complexity of complement-related diseasesSemantic proximity Read ↗

Genetic and acquired abnormalities in C3 glomerulopathy and primary immune complex-mediated MPGNSemantic proximity Read ↗

C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.Semantic proximity Read ↗

Treatment of C3 glomerulopathy with complement blockers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.